viewImmuPharma PLC

ImmuPharma says article shines light on potential of peptide subsidiary

Peptide drugs generated US$30bn in sales last year

Scientist pouring liquid into test tube
The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique

ImmuPharma PLC (LON:IMM) said peer-reviewed journal Nature Communications has carried an article assessing the potential of Urelix, a technology developed by its subsidiary Ureka.

The periodical has described for the first time the unique properties of oligourea foldamers as tools to improve the pharmaceutical properties of peptides.

There are more than 7,000 naturally occurring peptides that have crucial roles in human physiology, including actions as hormones, neurotransmitters and growth factors.

Around 140 peptide therapeutics are currently being developed, while currently around 60 have been approved by the US Food & Drug Administration generating sales last year of US$30bn.

However, as Dimitri Dimitriou, ImmuPharma's chief executive, pointed out: “Using natural peptides as drugs is not so effective because they are quickly broken down. 

“To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs.”

One of the first areas of focus for the Ureka researchers has been lookalikes for GLP-1, the basis of a number of drugs used to treat type II diabetes and non-alcoholic liver disease.

Scientists are also assessing the potential of using the Urelix to develop cancer drug candidates and as means of improving products already on the market.

The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique.

Quick facts: ImmuPharma PLC

Price: 17.85 GBX

Market: AIM
Market Cap: £29.87 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...



ImmuPharma's Tim McCarthy details Lupuzor licensing deal with Avion...

ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy caught up with Proactive's Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor -  its treatment for the autoimmune disease lupus. US speciality drugs group Avion Pharmaceuticals will fund...

1 week, 1 day ago

2 min read